Featured Head and Neck Cancer Clinical Trials

A Randomized Phase II Study of Adjuvant Concurrent Radiation and Chemotherapy versus Radiation Alone in Resected High – Risk Malignant Salivary Gland Tumors

Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy

IRB RTOG 1008 | CC CC00031 | Hospital Main Campus | Phase Phase 2 | Disease Head & Neck

Outcomes Registry of Patients with Head and Neck Cancer Undergoing Definitive Treatment at Cleveland Clinic

IRB CASE 4311 | CC CC00192 | Hospital Main Campus | Disease Head & Neck

A Phase II Trial of modified FOLFOX-6 Induction Chemotherapy followed by Esophagectomy and post-operative response based chemoradiotherapy in patients with locoregionally advanced adenocarcinoma of the esophagus, gastro-esophageal junction, and gastric cardia.

IRB CASE 6213 | CC 13-1422 | Hospital Fairview, Hillcrest, Main Campus, Mansfield, North Coast Cancer, Strongsville, Wooster | Disease Esophageal, Head & Neck

Randomized Phase II and Phase III Studies of Individualized Treatment for Nasopharyngeal Carcinoma Based on Biomarker Epstein Barr Virus (EBV) Deoxyribonucleic Acid (DNA)

IRB NRG HN001 | CC 14-691 | Hospital Beachwood, Fairview, Hillcrest, Independence, Main Campus, Mansfield, North Coast Cancer, Strongsville, Wooster | Phase Phase 2, Phase 3| Disease Head & Neck

A Phase II Study of the Addition of Pembrolizumab to Postoperative Radiotherapy in Resected High Risk Cutaneous Squamous Cell Cancer of the Head and Neck

IRB CASE 6316 | CC 17-069 | Hospital Fairview, Hillcrest, Main Campus | Phase Phase 2 | Disease Head & Neck

A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Of Atezolizumab (Anti-Pd-L1 Antibody) As Adjuvant Therapy After Definitive Local Therapy In Patients With High-Risk Locally Advanced Squamous Cell Carcinoma Of The Head And Neck

Feasibility Study of Temporally Feathered Radiation Therapy (TFRT) for Head and Neck Squamous Cell Carcinoma: Means of Toxicity Reduction

IRB CASE 4318 | CC 18-1248 | Hospital Main Campus | Disease Head & Neck

Phase II Study of IMRT Re-Irradiation with concurrent/adjuvant Nivolumab in patients with locoregionally recurrent or second primary squamous cell cancer of the head and neck

A randomized Phase II study of re-irradiation of SBRT plus anti-PD-1 antibody Pembrolizumab (Keytruda®) versus SBRT Kalone for locoregionally recurrent or second primary head and neck carcinoma